FDA approves wearable infusion device for advanced Parkinson disease
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
MedPage Today7h
Why Did a GLP-1 Receptor Agonist Fail This Parkinson's Trial?
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
Supernus: New Approval Holds Promise Of Increased Growth
Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...
GlobalData on MSN11h
AstraZeneca’s diabetes drug fails to slow Parkinson’s progression in UCL trial
Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
Diabetes drug similar to Ozempic showed no benefits for patients with Parkinson’s disease
A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...
Daniel Barenboim Announces He Has Parkinson’s Disease
Daniel Barenboim, the eminent conductor and pianist who stepped back from engagements in recent years citing health concerns, ...
manilatimes14h
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update
Gain's lead program in Parkinson's disease has been awarded funding support from The Michael J. Fox Foundation for ...
Psychology Today14h
A Suggested Revolution in Parkinson’s Research
We spend billions searching for the cures to chronic illnesses while neglecting research that could make the daily lives of ...
Supernus wins FDA approval for Parkinson’s pump on fourth try
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...
She was diagnosed with Parkinson’s at 27. These were her warning signs.
People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.